Pharmacokinetic issues in cancer chemoprevention

P. M. Plezia, Y. M. Peng, M. J. Xu, David S Alberts

Research output: Contribution to journalArticle

Abstract

Pharmacokinetic studies have recently become an integral aspect of chemopreventive drug development. Early trials, based largely on epidemiologic studies, used drug doses and schedules derived empirically. Pharmacokinetic issues of chemopreventive drug development and trial design, conduct, and interpretation are illustrated with examples of retinoid and beta-carotene studies from the Arizona Cancer Center Chemoprevention Program.

Original languageEnglish (US)
Pages (from-to)504-506
Number of pages3
JournalCancer Bulletin
Volume43
Issue number6
StatePublished - 1991

Fingerprint

Chemoprevention
Pharmacokinetics
Pharmaceutical Preparations
Neoplasms
Retinoids
beta Carotene
Epidemiologic Studies
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research

Cite this

Plezia, P. M., Peng, Y. M., Xu, M. J., & Alberts, D. S. (1991). Pharmacokinetic issues in cancer chemoprevention. Cancer Bulletin, 43(6), 504-506.

Pharmacokinetic issues in cancer chemoprevention. / Plezia, P. M.; Peng, Y. M.; Xu, M. J.; Alberts, David S.

In: Cancer Bulletin, Vol. 43, No. 6, 1991, p. 504-506.

Research output: Contribution to journalArticle

Plezia, PM, Peng, YM, Xu, MJ & Alberts, DS 1991, 'Pharmacokinetic issues in cancer chemoprevention', Cancer Bulletin, vol. 43, no. 6, pp. 504-506.
Plezia PM, Peng YM, Xu MJ, Alberts DS. Pharmacokinetic issues in cancer chemoprevention. Cancer Bulletin. 1991;43(6):504-506.
Plezia, P. M. ; Peng, Y. M. ; Xu, M. J. ; Alberts, David S. / Pharmacokinetic issues in cancer chemoprevention. In: Cancer Bulletin. 1991 ; Vol. 43, No. 6. pp. 504-506.
@article{d735c9cd382b4ed9ad0bb2c812ebbd02,
title = "Pharmacokinetic issues in cancer chemoprevention",
abstract = "Pharmacokinetic studies have recently become an integral aspect of chemopreventive drug development. Early trials, based largely on epidemiologic studies, used drug doses and schedules derived empirically. Pharmacokinetic issues of chemopreventive drug development and trial design, conduct, and interpretation are illustrated with examples of retinoid and beta-carotene studies from the Arizona Cancer Center Chemoprevention Program.",
author = "Plezia, {P. M.} and Peng, {Y. M.} and Xu, {M. J.} and Alberts, {David S}",
year = "1991",
language = "English (US)",
volume = "43",
pages = "504--506",
journal = "Cancer Bulletin",
issn = "0008-5448",
publisher = "Medical Arts Publishing",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetic issues in cancer chemoprevention

AU - Plezia, P. M.

AU - Peng, Y. M.

AU - Xu, M. J.

AU - Alberts, David S

PY - 1991

Y1 - 1991

N2 - Pharmacokinetic studies have recently become an integral aspect of chemopreventive drug development. Early trials, based largely on epidemiologic studies, used drug doses and schedules derived empirically. Pharmacokinetic issues of chemopreventive drug development and trial design, conduct, and interpretation are illustrated with examples of retinoid and beta-carotene studies from the Arizona Cancer Center Chemoprevention Program.

AB - Pharmacokinetic studies have recently become an integral aspect of chemopreventive drug development. Early trials, based largely on epidemiologic studies, used drug doses and schedules derived empirically. Pharmacokinetic issues of chemopreventive drug development and trial design, conduct, and interpretation are illustrated with examples of retinoid and beta-carotene studies from the Arizona Cancer Center Chemoprevention Program.

UR - http://www.scopus.com/inward/record.url?scp=0026316691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026316691&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 504

EP - 506

JO - Cancer Bulletin

JF - Cancer Bulletin

SN - 0008-5448

IS - 6

ER -